The TP53 mutations usually occur more frequently in advanced cancer patients, metastatic disease sites and undifferentiated tumors and can be used to predict chemotherapy or radiotherapy resistance (Shih et al., 2008; Altintas and Tothill, 2012). This evidence concerns the gene TP53 and metastatic neoplasm.